Merck
Executive Summary
Merck closes Rosetta Inpharmatics acquisition July 19. The $620 mil. deal was announced in May (1"The Pink Sheet" May 14, p.10)
You may also be interested in...
Merck/Rosetta Scales Up Merck's Genomics Effort, Merger Comfort Level?
Merck's $620 mil. acquisition offer for Rosetta Inpharmatics will scale up Merck's genomics research efforts - and may also scale up its tolerance for mergers and acquisitions.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials